Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK)
- Previous Close
11.500 - Open
11.500 - Bid 11.320 x --
- Ask 11.360 x --
- Day's Range
11.320 - 11.540 - 52 Week Range
11.320 - 23.800 - Volume
1,815,000 - Avg. Volume
3,126,094 - Market Cap (intraday)
57.655B - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
11.79 - EPS (TTM)
0.960 - Earnings Date --
- Forward Dividend & Yield 0.46 (4.00%)
- Ex-Dividend Date Jul 31, 2023
- 1y Target Est
19.48
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, anti-infection, API's and intermediate, metabolism, alimentary system, cardiovascular and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services, and investment management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
www.fosunpharma.com40,370
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 2196.HK
Performance Overview: 2196.HK
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2196.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2196.HK
Valuation Measures
Market Cap
58.59B
Enterprise Value
79.72B
Trailing P/E
11.94
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.69
Price/Book (mrq)
0.62
Enterprise Value/Revenue
1.93
Enterprise Value/EBITDA
10.55
Financial Highlights
Profitability and Income Statement
Profit Margin
5.76%
Return on Assets (ttm)
0.67%
Return on Equity (ttm)
5.23%
Revenue (ttm)
41.4B
Net Income Avi to Common (ttm)
2.39B
Diluted EPS (ttm)
0.960
Balance Sheet and Cash Flow
Total Cash (mrq)
15.58B
Total Debt/Equity (mrq)
61.88%
Levered Free Cash Flow (ttm)
-4.05B